2,5-Dimethyl-benzyl-ethylether | 91967-66-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,5-Dimethyl-benzyl-ethylether
• 英文别名: 2-(Ethoxymethyl)-1,4-dimethylbenzene
• CAS: 91967-66-7
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: LTLUVMRTFCXYDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,5-dimethylphenylmagnesium bromide 、 氯甲基乙醚 生成 2,5-Dimethyl-benzyl-ethylether
  参考文献：
  名称：

  Lapkin,I.I.; Mukhina,R.G., Journal of general chemistry of the USSR, 1961, vol. 31, p. 3732 - 3736

  摘要：

  DOI：

文献信息

• 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20090036444A1

  公开（公告）日：2009-02-05

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性，是一种预防或治疗丙型肝炎的药剂。
• Fused-ring compounds and use thereof as drugs
  申请人：Hashimoto Hiromasa

  公开号：US20070032497A1

  公开（公告）日：2007-02-08

  The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.

  本发明提供了以下式[I]的融合环化合物，其中每个符号如规范中定义的，其药学上可接受的盐以及包含该化合物的丙型肝炎治疗剂。本发明的化合物显示出基于丙型肝炎病毒（HCV）聚合酶抑制活性的抗HCV作用，并且可用作丙型肝炎的治疗剂或预防剂。
• TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Oka Takahiro

  公开号：US20120070409A1

  公开（公告）日：2012-03-22

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其表示为以下公式[I]，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，可用作预防或治疗丙型肝炎的药物。
• 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Mizojiri Ryo

  公开号：US20120020920A1

  公开（公告）日：2012-01-26

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]所表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明化合物基于HCV聚合酶抑制活性具有抗HCV活性，可用作预防或治疗丙型肝炎的药剂。
• POLYMER ELECTROLYTE, CROSSLINKED POLYMER ELECTROLYTE, POLYMER ELECTROLYTE MEMBRANE AND USE OF THE SAME
  申请人：Yamada Takashi

  公开号：US20110081597A1

  公开（公告）日：2011-04-07

  The present invention provides a polymer electrolyte, a crosslinked polymer electrolyte, a polymer electrolyte membrane and use of the same. The polymer electrolyte has a repeating unit represented by the following formula (1) in its molecule and an ion-exchange group in the molecule: wherein Ar represents an optionally substituted aromatic group; R 1 represents a hydrogen atom or an organic group; X represents a direct bond or a divalent group; n represents an integer of 1 to 3; and when n is 2 or more, the plurality of R 1 's may be the same as or different from each other.